alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit
10.16


 


Amendment


to the


Mason Slaine


Employment Agreement


 


This Amendment (the “Amendment”) to the Employment Agreement by and
between Information Holdings, Inc. (the “Company”) and Mason Slaine (the
“Executive”), dated as of April 30, 2002 (the “Employment Agreement”), is
entered into as of this 17th day of January, 2003.


 


WHEREAS, the Company and the Executive are presently parties to the
Employment Agreement; and


 


WHEREAS, the Company and the Executive desire to amend the Employment
Agreement as set forth herein.


 


NOW, THEREFORE, in consideration of the premises and the mutual
agreements hereinafter contained, the parties do hereby amend the Employment
Agreement as follows:


 


1.                                       By
deleting the last paragraph of Section 6(e) in its entirety, and replacing it
with the following:


 


In the event that Executive resigns pursuant
to this Section 6(e) or if the Company terminates Executive’s employment
without Just Cause following a Change of Control, the company shall pay to
Executive in a lump sum an amount equal to three times (i) the Salary in effect
immediately prior to the termination of employment plus (ii) the Bonus
Executive received for the fiscal year immediately prior to the fiscal year in
which his termination of employment occurred; provided, however,
that if such Change of Control occurs in calendar year 2003, the Salary
described in clause (i) above shall equal the Salary as in effect at the time
of such Change of Control, and the Bonus described in clause (ii) above shall
equal 50% of the Salary as in effect at the time of such Change of
Control.  Payments pursuant to this
Section 6(e) shall not apply to termination of Executive’s employment on
account of his death.


 


2.                                       Except
as provided herein and to the extent necessary to give full effect to the
provisions of this Agreement, the terms of the Employment Agreement shall
remain in full force and effect.


 


*              *              *


 


[Signatures appear on the following page.]


 

















 


IN WITNESS WHEREOF, the parties hereto have entered into this Agreement
effective as of the date first above written.


 


	
   

  	
  INFORMATION HOLDINGS, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Vincent A. Chippari

  	
   

  	
   

  
	
   

  	
  By: 
  Vincent A. Chippari

  	
   

  
	
   

  	
  Title: 
  Executive V.P. & CFO

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Mason Slaine

  	
   

  	
   

  
	
   

  	
  Mason Slaine

  	
   

  
					



 


2
§ 884.5940 Powered vaginal muscle stimulator for therapeutic use. ( a ) *Identification.* A powered vaginal muscle stimulator is an electrically powered device designed to stimulate directly the muscles of the vagina with pulsating electrical current. This device is intended and labeled for therapeutic use in increasing muscular tone and strength in the treatment of sexual dysfunction. This generic type of device does not include devices used to treat urinary incontinence.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP for a device is required to be filed with the Food and Drug Administration on or before July 12, 2000, for any powered vaginal muscle stimulator for therapeutic use that was in commercial distribution before May 28, 1976, or that has, on or before July 12, 2000, been found to be substantially equivalent to a powered vaginal muscle stimulator that was in commercial distribution before May 28, 1976. Any other powered vaginal muscle stimulator for therapeutic use shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
[45 FR 12684, Feb. 26, 1980, as amended at 52 FR 17741, May 11, 1987; 65 FR 19834, Apr. 13, 2000]
Exhibit 99.2

CERTIFICATION PURSUANT TO  SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the
undersigned, as Chief Financial Officer of The Timberland Company (the "Company"), does hereby certify that to the undersigned's knowledge:



| |  | /s/BRIAN P. MCKEONBrian P. McKeon Chief Financial
Officer
| |  | ---------------------------------------------------------

Date:
November 8, 2002

---

QuickLinks
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6910 Wheeled stretcher. ( a ) *Identification.* A wheeled stretcher is a device consisting of a platform mounted on a wheeled frame that is designed to transport patients in a horizontal position. The device may have side rails, supports for fluid infusion equipment, and patient securement straps. The frame may be fixed or collapsible for use in an ambulance.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 63 FR 59229, Nov. 3, 1998]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5600 Venturi mask. ( a ) *Identification.* A venturi mask is a device containing an air-oxygen mixing mechanism that dilutes 100 percent oxygen to a predetermined concentration and delivers the mixed gases to a patient.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
**Exhibit 23**

**Consent of Independent Registered Public Accounting Firm**

The Board of Directors 

ViroPharma Incorporated: 

We consent to the incorporation by reference inthe registration statements on Form S-8 (No. 333-152724, No. 333-136447, No. 333-34129, No. 333-38248, No. 333-60951, No. 333-38256, No. 333-109600 and No. 333-127188), registration statements on Form S-3 (No.333-156422, No. 333-37960, No. 333-64482, No. 333-99533, No. 333-122315, No. 333-123994, and No. 333-141411) and registration statement on Form S-4 (No. 333-153088) of ViroPharma Incorporated of our reports datedFebruary 27, 2009, with respect to the consolidated balance sheets of ViroPharma Incorporated as of December 31, 2008 and 2007, and the related consolidated statements of operations, comprehensive income, stockholders’ equity and cashflows for each of the years in the three-year period ended December 31, 2008 and the effectiveness of internal control over financial reporting as of December 31, 2008, which reports appear in the December 31, 2008 Annual Report onForm 10-K of ViroPharma Incorporated. Our report on the consolidated financial statements refers to the Company’s adoption of the provisions of Statement of Financial Accounting Standards No. 157, “Fair Value Measurements,”effective January 1, 2008, Financial Accounting Standards Board Interpretation No. 48, “Accounting for Uncertainty in Income Taxes” effective January 1, 2007 and Statement of Financial Accounting Standards No. 123R,“Share-Based Payment,” effective January 1, 2006. 

/s/ KPMG LLP 

Short Hills, NJ 

February 27, 2009
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2860 Heart sound transducer. ( a ) *Identification.* A heart sound transducer is an external transducer that exhibits a change in mechanical or electrical properties in relation to sounds produced by the heart. This device may be used in conjunction with a phonocardiograph to record heart sounds.
( b ) *Classification.* Class II (performance standards).
§ 876.5090 Suprapubic urological catheter and accessories. ( a ) *Identification.* A suprapubic urological catheter and accessories is a flexible tubular device that is inserted through the abdominal wall into the urinary bladder with the aid of a trocar and cannula. The device is used to pass fluids to and from the urinary tract. This generic type of device includes the suprapubic catheter and tube, Malecot catheter, catheter punch instrument, suprapubic drainage tube, and the suprapubic cannula and trocar.
( b ) *Classification.* ( 1 ) Class II (performance standards).
( 2 ) Class I for the catheter punch instrument, nondisposable cannula and trocar, and gastro-urological trocar. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 61 FR 1122, Jan. 16, 1996; 66 FR 38801, July 25, 2001]
[ARTICLE] 5
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   3-MOS
[FISCAL-YEAR-END]                          DEC-27-1997
[PERIOD-END]                               SEP-26-1997
[CASH]                                          21,098
[SECURITIES]                                         0
[RECEIVABLES]                                    4,153
[ALLOWANCES]                                        39
[INVENTORY]                                      4,189
[CURRENT-ASSETS]                                48,994
[PP&E]                                         292,835
[DEPRECIATION]                                 118,376
[TOTAL-ASSETS]                                 231,027
[CURRENT-LIABILITIES]                           35,858
[BONDS]                                         24,672
[COMMON]                                         2,185
[PREFERRED-MANDATORY]                            2,186
[PREFERRED]                                          0
[OTHER-SE]                                     161,059
[TOTAL-LIABILITY-AND-EQUITY]                   231,027
[SALES]                                        257,507 
[TOTAL-REVENUES]                               261,227
[CGS]                                          121,385
[TOTAL-COSTS]                                  227,829
[OTHER-EXPENSES]                                     0
[LOSS-PROVISION]                                     0
[INTEREST-EXPENSE]                               2,148  
[INCOME-PRETAX]                                 33,398
[INCOME-TAX]                                    13,459
[INCOME-CONTINUING]                             19,939
[DISCONTINUED]                                       0
[EXTRAORDINARY]                                      0
[CHANGES]                                            0
[NET-INCOME]                                    19,939
[EPS-PRIMARY]                                     1.04
[EPS-DILUTED]                                     1.04
</TABLE>
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1925 Ultrasonic scanner calibration test block. ( a ) *Identification.* An ultrasonic scanner calibration test block is a block of material with known properties used to calibrate ultrasonic scanning devices (e.g., the echoencephalograph).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 882.9.
[44 FR 51730, Sept. 4, 1979, as amended at 59 FR 63011, Dec. 7, 1994; 66 FR 38807, July 25, 2001]
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.3200 Artificial eye. ( a ) *Identification.* An artificial eye is a device resembling the anterior portion of the eye, usually made of glass or plastic, intended to be inserted in a patient's eye socket anterior to an orbital implant, or the eviscerated eyeball, for cosmetic purposes. The device is not intended to be implanted.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9, if the device is made from the same materials, has the same chemical composition, and uses the same manufacturing processes as currently legally marketed devices.
[61 FR 1124, Jan. 16, 1996, as amended at 66 FR 38813, July 25, 2001]
December 15, 2016

JUDGMENT

The Fourteenth Court of Appeals

RUFUS FREDERIC KIRBY, Appellant

NO. 14-16-00865-CR V.

THE STATE OF TEXAS, Appellee

________________________________

This cause was heard on the transcript of the record of the court below. The 

record indicates that the appeal should be DISMISSED. The Court orders the 

appeal DISMISSED in accordance with its opinion.

We further order this decision certified below for observance.
----- Forwarded by Jeb Stenhouse/DC/USEPA/US on 12/15/2011 09:04AM -----

To: Christine_J._Kymn@omb.eop.gov From : Jeb Stenhouse/DC/USEPA/US Date: 12/13/2011 08:55PM Cc: Sam Napolitano/DC/USEPA/US@EPA Subject: Re: Final Transport Rule ozone supplemental rulemaking - final draft responding to interagency comments (See attached file: EO 12866_SupplementalEO 12866 13563 Interagency Comments1 Supplemental Transport Final_EPA response to interagency comments 12 - 13 - 11_to OMB at 845pm_redline.docx) (See attached file: SNPR final budget TSD_12 - 7 - 11 FINAl_to OMB_v2 to OMB 12 - 13 - 11.docx) Hi Christine, Here are updated drafts of the preamble and TSD that reflect the edits you requested regarding the final Transp ort Rule RIA. Sincerely, Jeb Stenhouse Chief, Program Development Branch Clean Air Markets Division US Environmental Protection Agency 202 - 343 - 9781 stenhouse.jeb@epa.gov

-----Jeb Stenhouse/DC/USEPA/US wrote: ----- To: "Kymn , Christine J." <Christine_J._Kymn@omb.eop.gov> From : Jeb Stenhouse/DC/USEPA/US Date: 12/13/2011 03:56PM Cc: Sam Napolitano/DC/USEPA/US@EPA Subject: Re: Final Transport Rule ozone supplemental rulemaking - final draft responding to interagency comments Hi Christine - I neglected to attach a companion document showing you the budget comparisons that I understand you and Sam discussed earlier today. Here it is! (See attached file: Ozone Season Budget Comparisons for OMB 12 - 13 - 11.docx) Sincerely, Jeb Stenhouse Chief, Program Development Branch Clean Air Markets Division Environmental Protection Agency 202 - 343 - 9781 stenhouse.jeb@epa.gov Jeb Stenhouse --- 12/13/2011 03:12:24 PM --- Hi Christine, Sam asked me to send you a response draft that provides edits and explanations with re From : Jeb Stenhouse/DC/USEPA/US To: "Kymn , Christine J." <Christine_J._Kymn@o mb .eop.gov> Cc: Sam Napolitano/DC/USEPA/US@EPA Date: 12/13/2011 03:12 PMSubject: Final Transport Rule ozone supplemental rulemaking - final draft responding to interagency

comments Hi Christine, Sam asked me to send you a response draft that provides edits and explanations with regards to all of the comments we received from interagency review. Please note that I marked our responses with "EPA RESPONSE" in the margin comments, and the attached version is fully updated and shows you redline of the chan ges we made in response to interagency comments. This is now the latest version of the ozone supplemental preamble and rule text. (See attached file: EO 12866_SupplementalEO 12866 13563 Interagency Comments1 Supplemental Transport Final_EPA response to i nteragency comments 12 - 13 - 11_to OMB at 230pm_redline.docx) Sincerely, Jeb Stenhouse Chief, Program Development Branch Clean Air Markets Division Environmental Protection Agency 202 - 343 - 9781 stenhouse.jeb@epa.gov [attachment "EO 12866_SupplementalEO 12866 13563 Interagency Comments1 Supplemental Transport Final_EPA response to interagency comments 12 - 13 - 11_to OMB at 230pm_redline.docx" removed by Jeb Stenhouse/DC/USEPA/US] [attachment "Ozone Season Budget Compari sons for OMB 12 - 13 - 11.docx" removed by Jeb Stenhouse/DC/USEPA/US]
§ 876.4590 Interlocking urethral sound. ( a ) *Identification.* An interlocking urethral sound is a device that consists of two metal sounds (elongated instruments for exploring or sounding body cavities) with interlocking ends, such as with male and female threads or a rounded point and mating socket, used in the repair of a ruptured urethra. The device may include a protective cap to fit over the metal threads.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 61 FR 1122, Jan. 16, 1996; 66 FR 38801, July 25, 2001]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5480 Isocapnic ventilation device. ( a ) *Identification.* An isocapnic ventilation device is a prescription device used to administer a blend of carbon dioxide and oxygen gases to a patient to induce hyperventilation. This device may be labeled for use with breathing circuits made of reservoir bags (§ 868.5320), oxygen cannulas (§ 868.5340), masks (§ 868.5550), valves (§ 868.5870), resuscitation bags (§ 868.5915), and/or tubing (§ 868.5925).
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Nonclinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use, including the following performance characteristics: ( i ) Gas concentration accuracy testing for the range of intended concentrations;
( ii ) Airway pressure delivery accuracy testing;
( iii ) Supplemental O2 flowrate accuracy testing;
( iv ) Alarm testing; and
( v ) Use life testing.
( 2 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 3 ) Labeling must include the following: ( i ) Instructions for use;
( ii ) A precaution that monitoring of capnography is necessary during treatment with non-spontaneously breathing patients; and
( iii ) Use life specification.
[86 FR 68397, Dec. 2, 2021]
<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                         ------------------------------


                                    FORM 8-K

                                 CURRENT REPORT



                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                                  June 4, 1999
                        -------------------------------
                                 Date of Report
                        (Date of earliest event reported)



                         INTERLINQ SOFTWARE CORPORATION
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Washington                  0-25186                    91-1187540
       ---------------         ---------------------         -------------------
       (State or other         (Commission File No.)           (IRS Employer
       jurisdiction of                                       Identification No.)
        incorporation)

                             11980 N.E. 24th Street
                           Bellevue, Washington 98005
--------------------------------------------------------------------------------
          (Address of principal executive offices, including zip code)

                                 (425) 827-1112
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

<PAGE>   2
ITEM 5. OTHER EVENTS

        On June 4, 1999, INTERLINQ Software Corporation and Terlin, Inc., an
affiliate of W.R. Hambrecht + Co., LLC, mutually agreed to terminate their
Agreement and Plan of Merger dated December 29, 1998 (the "Merger Agreement")
relating to a proposed leveraged recapitalization of INTERLINQ. INTERLINQ agreed
to reimburse Terlin for its Transaction Expenses (as defined in the Merger
Agreement) incurred in connection with the proposed merger. Such reimbursement
(which may occur on one or more occasions) shall be paid within two business
days after delivery to INTERLINQ of a written request therefor, including
reasonable evidence of the expenses incurred. No other termination or break-up
fees will be paid.



                                       2
<PAGE>   3
                                    SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

                                       INTERLINQ SOFTWARE CORPORATION


Dated:  June 4, 1999
                                       By /s/ JIRI M. NECHLEBA
                                          --------------------------------------
                                          Jiri M. Nechleba
                                          President, Chief Executive Officer and
                                          Chairman of the Board



                                        3
<PAGE>   1

                                                                    EXHIBIT 23.3

                       CONSENT OF INDEPENDENT ACCOUNTANTS

     We hereby consent to the use in this Registration Statement on Form S-1 of
our report dated April 24, 1998 relating to the financial statements of Arcxel
Technologies, Inc., which appears in such Registration Statement. We also
consent to the references to us under the headings "Experts" and "Selected
Financial Data" in such Prospectus. However, it should be noted that
PricewaterhouseCoopers LLP has not prepared or certified "Selected Financial
Data" in such Registration Statement.

/s/ PRICEWATERHOUSECOOPERS LLP
---------------------------------------------------------
PricewaterhouseCoopers LLP
Seattle, Washington
June 22, 1999
§ 876.4770 Urethrotome. ( a ) *Identification.* A urethrotome is a device that is inserted into the urethra and used to cut urethral strictures and enlarge the urethra. It is a metal instrument equipped with a dorsal-fin cutting blade which can be elevated from its sheath. Some urethrotomes incorporate an optical channel for visual control.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 84 FR 71813, Dec. 30, 2019]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1117 B-type natriuretic peptide test system. ( a ) *Identification.* The B-type natriuretic peptide (BNP) test system is an in vitro diagnostic device intended to measure BNP in whole blood and plasma. Measurements of BNP are used as an aid in the diagnosis of patients with congestive heart failure.
( b ) *Classification.* Class II (special controls). The special control is “Class II Special Control Guidance Document for B-Type Natriuretic Peptide Premarket Notifications; Final Guidance for Industry and FDA Reviewers.”
[66 FR 12734, Feb. 28, 2001]